Verbal list learning and memory profiles in HIV-infected adults, Alzheimer’s disease, and Parkinson’s disease: An evaluation of the “cortical hypothesis” of NeuroAIDS

ABSTRACT

HIV+ population is getting older because of progress in treatments. Yet, there are concerns that Older HIV+ individuals (OHIV+) may be more vulnerable for developing a “cortical” dementia such as Alzheimer Disease (AD). Our aim was to explore the hypothesis that the cognitive deficit extends to ‘‘cortical’’ functions in OHIV+ by comparing serial position effects (SPE) in different groups of participants affected by “cortical” or “subcortical” damage. We enrolled a total of 122 subjects: 22 OHIV+ (≥60 years of age), 31 Younger HIV+ (YHIV+) (<60 years of age), 18 participants with AD, 23 subjects with Parkinson Disease (PD), and 28 healthy subjects. All subjects performed verbal learning tasks (VLT) to explore SPE. Factorial analysis of covariance showed a significant effect of “group” (p < 0.001) and “task” (Primacy vs Recency) (p < 0.001), but no significant group*task (p = 0.257) interaction. Compared with healthy subjects (p = 0.003), AD had the most severe reduction of Primacy, confirming a primary “encoding deficit,” while PD confirmed a “frontal pattern.” OHIV+ showed a memory profile similar to that of PD with a worsening of the cognitive performance in comparison with YHIV+. In conclusion, we did not confirm the “cortical” hypothesis in OHIV+, at least in terms of learning and memory functions.

KEYWORDS:

• Alzheimer disease (AD)
• cortical hypothesis
• human immunodeficiency virus (HIV)
• Parkinson disease (PD)
• serial position effects

Acknowledgments

No specific funding was received for this study.

M. Fabbiani received speakers’ honoraria from Merck Sharp & Dohme, Bristol-Myers Squibb, and Janssen-Cilag. R. Cauda has been advisor for Gilead and Janssen-Cilag, received speakers’ honoraria from ViiV, Bristol-Myers Squibb, Merck Sharp, and Dohme and Janssen-Cilag, and research support from “Fondazione Roma.” S. D. Giambenedetto received speakers’ honoraria and support for travel meetings from Gilead, Bristol-Myers Squibb, Abbott, Boehringer Ingelheim, Janssen-Cilag, and GlaxoSmithKline. All the other authors declare that they have not conflict of interest.